Project Grant R44DK143766
Award Date 9/10/25
Completion Date 8/31/26
Dollars Obligated $344K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $324,984 Project Grant was awarded on August 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Syntis Bio Inc., is developing an innovative oral therapy for treating homocystinuria, a rare metabolic disorder. The project involves optimizing a formulation that combines a protease-stable enzyme (methionine-gamma-lyase) with a...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $613,528 to the University of Massachusetts Medical School (UMMS) to evaluate the efficiency of in vivo gene transfer to correct the molecular neuropathology causing psychiatric disease in maple syrup urine disease (MSUD). MSUD is a severe, inherited amino acid metabolism disorder...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded Mucommune LLC a $359,608 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development and evaluation of a "pegloticase biobetter" - an improved version of the pegylated uricase enzyme therapy - for the sustained suppression of fructose-induced obesity. Elevated uric acid levels from excessive fructose consumption...
- This Project Grant award of $299,648 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports Cometa Therapeutics Inc.'s development of CMT-101, a novel adeno-associated virus (AAV)-based gene therapy to treat Glycogen Storage Disease 1B (GSD-1B). The funding will enable dose-finding and biodistribution studies, as well as pre-Investigational New Drug (IND)...
- This Project Grant award of $613,558 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports Genetobe Inc., a Michigan-based biotechnology company, in developing novel, selective sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor compounds as an adjunctive therapy for cystic fibrosis (CF) associated metabolic disorders, including CF-associated liver disease and CF-related diabetes. The...
- This federal Project Grant award of $500,000.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research by Tega Therapeutics Inc. to develop new clinical biomarkers for GM1 gangliosidosis, a lysosomal storage disease. The project aims to confirm whether levels of specific glycan metabolites in urine and/or cerebrospinal fluid reflect changes in...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $808,866 to Progenra Inc., a biotechnology firm located in Malvern, Pennsylvania. The funding supports research to evaluate novel small molecule compounds that activate the ubiquitin proteasome system (UPS) as potential therapeutics for treating acute and chronic pancreatitis. Key objectives include assessing...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,255,725 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Icahn School of Medicine at Mount Sinai. The funding will support the development of a solid-state fermentation platform for manufacturing defined live biotherapeutic products (LBPs) comprised of in vitro manufactured bacterial strains. This represents a scalable approach to...
- This federal Project Grant award of $305,786 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Cypress Biopharma, Inc. The grant supports research to develop a novel non-immunosuppressive therapy for childhood nephrotic syndrome (NS). The project aims to leverage the highly active metabolite of pioglitazone as a scaffold to design a drug that can...
- This federal Project Grant award of $358,039 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting research by Nous Biosciences Inc. to evaluate a combination therapy of dolcanatide (a guanylate cyclase-C agonist) and atiprimod (a JAK-STAT inhibitor) for the treatment of murine colitis. The research aims to advance understanding of the pathogenesis of...